Attached files
| file | filename |
|---|---|
| EX-99.2 - INVESTOR FACT SHEET - CHEMBIO DIAGNOSTICS, INC. | factsheet.pdf |
| EX-99.1 - PDF OF INVESTOR PRESENTATION - CHEMBIO DIAGNOSTICS, INC. | investorpresentation.pdf |
| EX-99.1 - WORD VERSION OF INVESTOR PRESENTATION - CHEMBIO DIAGNOSTICS, INC. | investorpresentation.htm |
| 8-K - FORM 8-K FOR PRESS RELEASE - CHEMBIO DIAGNOSTICS, INC. | form8_k.htm |
Corporate Fact Sheet
January 8, 2018
STOCK INFORMATION (as of January 5, 2018)
Ticker: CEMI
Exchange: Nasdaq
Share Price: $ 8.24/share
Market Cap: $101.5 Million
CORPORATE HIGHLIGHTS
A global leader in point-of-care (POC) infectious disease diagnostics
|
§
|
Sales in 40+ countries
|
|
§
|
Global commercialization organization servicing the U.S., Europe, Africa, Asia Pacific and Latin America
|
|
§
|
Operations and manufacturing in the U.S. and Southeast Asia
|
Groundbreaking patented DPP® technology platform
|
§
|
Superior sensitivity and specificity vs. traditional lateral flow technology
|
|
§
|
Multiple tests from a tiny (10uL) drop of fingertip blood (multiplexing)
|
Robust pipeline of new DPP® POC assays in development
|
§
|
DPP® HIV-Syphilis Combination Assay (U.S. version)
|
|
§
|
DPP® Fever Assays –Africa (Malaria, Dengue, Zika, Chikungunya, Ebola, Lassa, Marburg)
|
|
§
|
DPP®Fever Assay-Asia (Maleria, Dengue, Zika, Chikungunya, Leptospirosis, Rickettsia typhi, Burkholderia Pseudomallei Orientia tsutsugamushi.)
|
|
§
|
DPP® Technology Collaborations (Traumatic Brain Injury, Cancer, Bovine TB)
|
Multiple high-value collaborations
|
§
|
U.S. Government, HHS/ASPR/BARDA: Zika, Dengue, Chikungunya
|
|
§
|
Paul G. Allen Ebola Program: Fever Panel- Africa, Zika
|
|
§
|
Bill & Melinda Gates Foundation: Malaria Oral Fluid/Saliva
|
|
§
|
Centers for Disease Control & Prevention (CDC): Malaria, Ebola
|
|
§
|
FIND: Fever Panel- Asia
|
COMPANY SNAPSHOT
Chembio Diagnostics, Inc. (NASDAQ: CEMI) develops, manufactures, licenses and markets rapid diagnostic assays in the growing $8.0 billion point-of-care (POC) testing market. In addition to its branded and proprietary HIV and fever disease assays, which it sells in the U.S. and/or internationally, the Company has several ongoing collaborations for the development of diagnostic assays for Malaria, Dengue Fever, Zika, Ebola and other febrile illness, brain injury and a specific form of cancer.
Dual Path Platform (DPP®) is Chembio's patented POC technology, which offers significant advantages over lateral-flow technologies including enhanced sensitivity and the ability to conduct multiple tests from a single sample (multiplexing). DPP® continues to provide Chembio with a growing pipeline of business opportunities for the development and manufacture of new products.
CHEMBIO'S LEAD PRODUCTS
DPP® HIV-Syphilis Assay *available in selected non-U.S. markets
|
o
|
Rapid, multiplex detection of HIV 1, HIV 2 and syphilis using a single sample
|
DPP® HIV 1/2 Assay
|
o
|
Rapid detection of HIV 1 and HIV 2 antibodies in oral fluid and all blood matrices
|
HIV 1/2 STAT-PAK® Assay
|
o
|
Single-use, rapid, visual detection of HIV 1 and HIV 2 antibodies
|
SURE CHECK® HIV 1/2 Assay
|
o
|
Self-contained, single-use collection & testing device
|
(See graphics)
PAGE 2
CHEMBIO'S DPP® DUAL PATH PLATFORM
|
§
|
Patented technology
|
|
§
|
Allows improved sensitivity and specificity compared to lateral flow technology
|
|
§
|
Enables multiple test results via a single blood sample (e.g., HIV-Syphilis Combo Assay)
|
|
§
|
Utilized with DPP® Micro Reader for semi-quantitive results
|
|
§
|
Offers application within infectious disease and potential for a number of other indications
|
(See graphics)
SALES AND MARKETING
|
§
|
Global commercialization organization
|
|
§
|
Internal sales and marketing infrastructure
|
|
§
|
Partnerships with leading distributors
|
|
§
|
Experienced and accomplished leadership
|
|
§
|
Strategic base of operations in Southeast Asia
|
|
§
|
Sales organization servicing the U.S., Europe, Africa, Asia Pacific and Latin America
|
MANUFACTURING AND OPERATIONS
|
§
|
Operations in Medford, New York and Malaysia
|
|
§
|
High volume manufacturing capabilities
|
|
§
|
65,000 sq. ft. leased facilities
|
|
§
|
Robust quality management system
|
|
§
|
Regulatory access in Southeast Asia
|
|
§
|
Total employees: ~165
|
Sexually Transmitted Diseases
HIV
|
o
|
Approximately 37 million people living with HIV/AIDS worldwide (2015)
|
|
o
|
More than 1.1 million people in the U.S. are living with HIV infection, and approximately 1 in 8 are unaware of their infection
|
SYPHILIS
|
o
|
Approximately 12 million people globally become ill with syphilis annually (2015)
|
|
o
|
From 2005-2013, syphilis cases in the U.S. nearly doubled, from 8,724 to 16,663
|
Fever Diseases
Malaria
|
·
|
Approximately 214 million infections and 438,000 deaths annually (2015)
|
Dengue Fever
|
·
|
Approximately 390 million infections annually with 40% of the world population at risk (2013)
|
Ebola
|
·
|
Approximately 28,000 infections and 11,000 deaths in 2014 – 2015
|
Zika
|
·
|
Since 2015, the geographical range of Zika virus has expanded rapidly, with transmission reported in 60+ countries
|
DPP PIPELINE & COLLABOTATORS
Chembio Current Internal Development:
• DPP® HIV-Syphilis Assay (U.S. market)
• DPP® Malaria Assay
• DPP® Chikungunya Assay
Current Development Collaborations:
• DPP® Dengue Fever – Undisclosed collaborator
• DPP® Ebola & Febrile Illness – CDC Research Agreement
• DPP® Fever Panel – Africa- The Paul G. Allen Ebola Program
• DPP® Fever Panel – Asia- FIND
• DPP® Malaria OF/Saliva– The Bill & Melina Gates Foundation
• DPP® Zika Assay – The Paul G. Allen Family Foundation & HHS/BARDA
• DPP® Zika/Dengue/Chikungunya Assay – HHS/BARDA (HHS option)
• DPP® Traumatic Brain Injury – Perseus Science Group LLC
• DPP® Cancer (a specific form) – Undisclosed collaborator
• DPP® BovidTB Assay – U.S. Department of Agriculture
Tech Transfer and Distribution:
• DPP® technology for Geenius™ HIV 1/2 Confirmatory Assay – Bio Rad
• DPP® product distribution in Brazil – Oswaldo Cruz Foundation
• DPP® co-branding and distribution in Brazil – Labtest Diagnostica SA
SENIOR EXECUTIVE OFFICERS
John J. Sperzel III, Chief Executive Officer
Javan Esfandiari, M.S., Chief Science & Technology Officer
Neil A. Goldman CPA, EVP & Chief Financial Officer
Sharon Klugewicz, M.S., President, America's Region
Robert Passas, Ph.D, President, EMEA & APAC Regions
|
Chembio Diagnostics, Inc.
|
Investor Relations
|
Company Contact
|
|
3661 Horseblock Road
|
Vida Strategic Partners
|
Susan Norcott
|
|
Medford, NY 11763
|
Stephanie C. Diaz
|
631-924-1135 x125
|
|
Ph. 631-924-1135
|
(415) 675-7401
|
snorcott@chembio.com
|
|
Fax 631-924-2065
|
sdiaz@vidasp.com
|
|
|
www.chembio.com
|
|
|